focus -WSS

focus

author：knowledge 2025-10-01 05:40:04 - browse：126

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Rep. Raul Ruiz on the physician shortage and more

knowledge

WSS

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Tuskegee Airman Raymond Cassagnol dies at 102

Thousands protest in Iraq for a second day over burning of Quran in Sweden

J&J to emphasize cancer drugs, stop much of its vaccine research

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

explore

focus

hotspot

Peter Hotez and the public health issue of online harassment

Flagship Pioneering launches a new biotech in two countries

The cancer drug shortage isn’t new — and neither are the solutions

Rep. Raul Ruiz on the physician shortage and more

After affirmative action ruling, medical educators look to 'holistic review'

U.K. Biobank has 500,000 peoples' genome sequences available

Supreme Court strikes down use of affirmative action

Supreme Court strikes down Biden student loan forgiveness program

BioMarin wins approval for gene therapy to treat hemophilia A

What don’t we know about an Alzheimer’s drug side effect?

leisure time

Despite FDA concern, risk that CAR

Supreme Court strikes down Biden student loan forgiveness program

The EPA's new lead rule: How one expert crunched the numbers

Rep. Raul Ruiz on the physician shortage and more

Why do we get seasonal allergies?

ADA: All diabetes patients should be screened for liver condition

knowledge

knowledge

entertainment

focus